FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568400283> ?p ?o ?g. }

• W2568400283 endingPage "1265" @default.
• W2568400283 startingPage "1255" @default.
• W2568400283 abstract "Background The only potentially curative treatment for patients with colorectal liver metastases is hepatectomy. Associating liver partition and portal vein ligation for staged hepatectomy has emerged as a method of treatment for patients with inadequate future liver remnant. One concern about associating liver partition and portal vein ligation for staged hepatectomy is that preoperative chemotherapy may negatively affect the volume increase of the future liver remnant and outcomes. Methods This study from the International Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Registry (NCT01924741) includes 442 patients with colorectal liver metastases registered from 2012–2016. Future liver remnant hypertrophy (absolute increase, percent increase, and kinetic growth rate) and clinical outcome were analyzed retrospectively in relation to type and amount of chemotherapy. The analyzed groups included patients with no chemotherapy, 1 regimen of chemotherapy, >1 regimen, and a group that received monoclonal antibodies in addition to chemotherapy. Results Ninety percent of the patients received neoadjuvant oncologic therapy including 42% with 1 regimen of chemotherapy, 44% with monoclonal antibodies, and 4% with >1 regimen. Future liver remnant increased between 74–92% with the largest increase in the group with 1 regimen of chemotherapy. The increase in milliliters was between 241 mL (>1 regimen) and 306 mL (1 regimen). Kinetic growth rate was between 14–18% per week and was greatest for the group with 1 regimen of chemotherapy. No statistical significance was found between the groups with any of the measurements of future liver remnant hypertrophy. Conclusion Neoadjuvant chemotherapy, including monoclonal antibodies, does not negatively affect future liver remnant growth. Patients with colorectal liver metastases who might be potential candidates for associating liver partition and portal vein ligation for staged hepatectomy should be considered for neoadjuvant chemotherapy. The only potentially curative treatment for patients with colorectal liver metastases is hepatectomy. Associating liver partition and portal vein ligation for staged hepatectomy has emerged as a method of treatment for patients with inadequate future liver remnant. One concern about associating liver partition and portal vein ligation for staged hepatectomy is that preoperative chemotherapy may negatively affect the volume increase of the future liver remnant and outcomes. This study from the International Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Registry (NCT01924741) includes 442 patients with colorectal liver metastases registered from 2012–2016. Future liver remnant hypertrophy (absolute increase, percent increase, and kinetic growth rate) and clinical outcome were analyzed retrospectively in relation to type and amount of chemotherapy. The analyzed groups included patients with no chemotherapy, 1 regimen of chemotherapy, >1 regimen, and a group that received monoclonal antibodies in addition to chemotherapy. Ninety percent of the patients received neoadjuvant oncologic therapy including 42% with 1 regimen of chemotherapy, 44% with monoclonal antibodies, and 4% with >1 regimen. Future liver remnant increased between 74–92% with the largest increase in the group with 1 regimen of chemotherapy. The increase in milliliters was between 241 mL (>1 regimen) and 306 mL (1 regimen). Kinetic growth rate was between 14–18% per week and was greatest for the group with 1 regimen of chemotherapy. No statistical significance was found between the groups with any of the measurements of future liver remnant hypertrophy. Neoadjuvant chemotherapy, including monoclonal antibodies, does not negatively affect future liver remnant growth. Patients with colorectal liver metastases who might be potential candidates for associating liver partition and portal vein ligation for staged hepatectomy should be considered for neoadjuvant chemotherapy." @default.
• W2568400283 created "2017-01-13" @default.
• W2568400283 creator A5001426029 @default.
• W2568400283 creator A5002026296 @default.
• W2568400283 creator A5007647741 @default.
• W2568400283 creator A5009723409 @default.
• W2568400283 creator A5023004084 @default.
• W2568400283 creator A5026967063 @default.
• W2568400283 creator A5027331253 @default.
• W2568400283 creator A5039546580 @default.
• W2568400283 creator A5044921867 @default.
• W2568400283 creator A5047322432 @default.
• W2568400283 creator A5055117557 @default.
• W2568400283 creator A5058538515 @default.
• W2568400283 creator A5084062479 @default.
• W2568400283 creator A5084843997 @default.
• W2568400283 date "2017-05-01" @default.
• W2568400283 modified "2023-10-17" @default.
• W2568400283 title "Neoadjuvant chemotherapy does not affect future liver remnant growth and outcomes of associating liver partition and portal vein ligation for staged hepatectomy" @default.
• W2568400283 cites W1818318323 @default.
• W2568400283 cites W1981963963 @default.
• W2568400283 cites W1985899126 @default.
• W2568400283 cites W1997275828 @default.
• W2568400283 cites W1999583653 @default.
• W2568400283 cites W2004308769 @default.
• W2568400283 cites W2004959196 @default.
• W2568400283 cites W2016726396 @default.
• W2568400283 cites W2016912036 @default.
• W2568400283 cites W2030570667 @default.
• W2568400283 cites W2032134516 @default.
• W2568400283 cites W2036679114 @default.
• W2568400283 cites W2037651699 @default.
• W2568400283 cites W2038745124 @default.
• W2568400283 cites W2039272512 @default.
• W2568400283 cites W2042360445 @default.
• W2568400283 cites W2043049566 @default.
• W2568400283 cites W2044808785 @default.
• W2568400283 cites W2044985115 @default.
• W2568400283 cites W2049399730 @default.
• W2568400283 cites W2052294821 @default.
• W2568400283 cites W2058135488 @default.
• W2568400283 cites W2058242433 @default.
• W2568400283 cites W2058491683 @default.
• W2568400283 cites W2066040529 @default.
• W2568400283 cites W2072925972 @default.
• W2568400283 cites W2073776989 @default.
• W2568400283 cites W2082462577 @default.
• W2568400283 cites W2085773264 @default.
• W2568400283 cites W2092143175 @default.
• W2568400283 cites W2096998881 @default.
• W2568400283 cites W2120917587 @default.
• W2568400283 cites W2121656227 @default.
• W2568400283 cites W2122750846 @default.
• W2568400283 cites W2131745440 @default.
• W2568400283 cites W2136567165 @default.
• W2568400283 cites W2138235363 @default.
• W2568400283 cites W2144326782 @default.
• W2568400283 cites W2146607441 @default.
• W2568400283 cites W2151081558 @default.
• W2568400283 cites W2154692607 @default.
• W2568400283 cites W2171397731 @default.
• W2568400283 cites W2334206457 @default.
• W2568400283 cites W2344724773 @default.
• W2568400283 cites W4376635667 @default.
• W2568400283 doi "https://doi.org/10.1016/j.surg.2016.11.033" @default.
• W2568400283 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28081953" @default.
• W2568400283 hasPublicationYear "2017" @default.
• W2568400283 type Work @default.
• W2568400283 sameAs 2568400283 @default.
• W2568400283 citedByCount "14" @default.
• W2568400283 countsByYear W25684002832017 @default.
• W2568400283 countsByYear W25684002832018 @default.
• W2568400283 countsByYear W25684002832020 @default.
• W2568400283 countsByYear W25684002832021 @default.
• W2568400283 countsByYear W25684002832022 @default.
• W2568400283 countsByYear W25684002832023 @default.
• W2568400283 crossrefType "journal-article" @default.
• W2568400283 hasAuthorship W2568400283A5001426029 @default.
• W2568400283 hasAuthorship W2568400283A5002026296 @default.
• W2568400283 hasAuthorship W2568400283A5007647741 @default.
• W2568400283 hasAuthorship W2568400283A5009723409 @default.
• W2568400283 hasAuthorship W2568400283A5023004084 @default.
• W2568400283 hasAuthorship W2568400283A5026967063 @default.
• W2568400283 hasAuthorship W2568400283A5027331253 @default.
• W2568400283 hasAuthorship W2568400283A5039546580 @default.
• W2568400283 hasAuthorship W2568400283A5044921867 @default.
• W2568400283 hasAuthorship W2568400283A5047322432 @default.
• W2568400283 hasAuthorship W2568400283A5055117557 @default.
• W2568400283 hasAuthorship W2568400283A5058538515 @default.
• W2568400283 hasAuthorship W2568400283A5084062479 @default.
• W2568400283 hasAuthorship W2568400283A5084843997 @default.
• W2568400283 hasConcept C121608353 @default.
• W2568400283 hasConcept C126322002 @default.
• W2568400283 hasConcept C141071460 @default.
• W2568400283 hasConcept C143998085 @default.
• W2568400283 hasConcept C159110652 @default.
• W2568400283 hasConcept C2776694085 @default.
• W2568400283 hasConcept C2776909242 @default.

• next